Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VTP-02
- Development stage
- Unknown
- Lead developer
- Var2 Pharmaceuticals
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
VTP-02 is a radiopharmaceutical candidate in Phase 1 development by Var2 Pharmaceuticals for cancer imaging and potential radiotherapeutic applications. The molecule is a recombinant fusion protein comprising a single-chain variable fragment (scFv) of Vartumab, which targets oncofetal chondroitin sulfate (ofCS), a tumor-specific glycosaminoglycan modification found on a wide range of solid tumors but absent from most healthy tissues. To optimize pharmacokinetics, the scFv is fused to an albumin-binding domain (ABD) to extend its circulatory half-life. For positron emission tomography (PET) imaging, the construct is conjugated to the radioisotope Zirconium-89 (89Zr) using a deferoxamine (DFO) chelator. VTP-02 is designed to enable the detection and monitoring of ofCS-expressing tumors, serving as a diagnostic component of a theranostic platform.
- Other names
- Vartumab F8-scFv-ABD-DFO-89Zr
02
Targets
ofCS (Oncofetal chondroitin sulfate)
Beyond the preview
Go deeper on VTP-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VTP-02.